Brief: Eisai Completes Rolling BLA Submission For Subcutaneous Maintenance Dosing Of Leqembi® (Lecanemab-Irmb) In The Us
31/10/2024 23:31
Oct 31 (Reuters) - BioArctic AB BIOAb.ST :
* EISAI COMPLETES ROLLING BLA SUBMISSION FOR SUBCUTANEOUS
MAINTENANCE DOSING OF LEQEMBI® (LECANEMAB-IRMB) IN THE US
Source text: ID:nWkr7XPYCd
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million